Greater Cannabis Company (GCAN) Total Current Liabilities (2016 - 2026)
Greater Cannabis Company's (GCAN) quarterly Total Current Liabilities came in at $776464.0 in Q1 2026, down 23.05% year-on-year from $1.0 million in Q1 2025, and up 4.58% quarter-over-quarter from $742464.0 in Q4 2025.
Greater Cannabis Company (GCAN) Total Current Liabilities (2016 - 2026) Analysis & Trends
Greater Cannabis Company's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $776464.0 for Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 23.05% year-over-year to $776464.0 in Q1 2026; TTM through Mar 2026 was $776464.0, a 23.05% decrease from a year earlier, with the FY2025 full-year figure at $742464.0, down 17.33% from the prior year.
- Total Current Liabilities rose to $776464.0 in Q1 2026 per GCAN's latest filing, from $742464.0 in the prior quarter.
- Across five years, Total Current Liabilities topped out at $1.1 million in Q3 2025 and bottomed at $742464.0 in Q4 2025.
- The 5-year median for Total Current Liabilities is $860874.0 (2024), against an average of $897704.7.
- Across the five-year window, Total Current Liabilities soared 44.13% in 2022 and dropped 23.05% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $825277.0 in 2022, then advanced by 1.0% to $833508.0 in 2023, then advanced by 7.74% to $898058.0 in 2024, then dropped by 17.33% to $742464.0 in 2025, then increased by 4.58% to $776464.0 in 2026.
- Per Business Quant, the three latest GCAN Total Current Liabilities figures stand at $776464.0 (Q1 2026), $742464.0 (Q4 2025), and $1.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | 776,464.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 776,464.00 |
| Dec 31, 2025 | 742,464.00 |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 898,058.00 |
| Sep 30, 2024 | 860,874.00 |
| Jun 30, 2024 | 833,993.00 |
| Mar 31, 2024 | 839,333.00 |
| Dec 31, 2023 | 833,508.00 |
| Sep 30, 2023 | 856,570.00 |
| Jun 30, 2023 | 881,605.00 |
| Mar 31, 2023 | 848,618.00 |
| Dec 31, 2022 | 825,277.00 |
| Sep 30, 2022 | 862,190.00 |
| Jun 30, 2022 | 965,767.00 |
| Mar 31, 2022 | 998,504.00 |
| Dec 31, 2021 | 861,999.00 |
| Sep 30, 2021 | 782,506.00 |
| Jun 30, 2021 | 670,049.00 |